Progress on safety of subcutaneous immunotherapy
10.3760/cma.j.issn.1673-4408.2021.12.004
- VernacularTitle:皮下免疫治疗安全性的研究进展
- Author:
Yang XU
1
;
Changshan LIU
Author Information
1. 天津医科大学第二医院儿科 300211
- Keywords:
Subcutaneous immunotherapy;
Safety;
Adverse reactions
- From:
International Journal of Pediatrics
2021;48(12):808-812
- CountryChina
- Language:Chinese
-
Abstract:
Allergic diseases are a kind of common chronic diseases, whose treatment cycle is long and easy to be repeated, which causes heavy medical and economic burden to the whole world.Allergen immunotherapy(AIT) is the cause-specific therapy for IgE mediated allergic diseases and can change the course of allergic diseases.Although numerous clinical studies have demonstrated the efficacy and safety of AIT in the treatment of allergic diseases, severe and even fatal adverse reactions still occur, especially in subcutaneous immunotherapy(SCIT). This review mainly focuses on the latest research progress of SCIT safety, and summarizes the research status, risk factors, countermeasures and future research directions of SCIT adverse reactions.
